Nevro Statistics
Total Valuation
Biogen has a market cap or net worth of $18.73 billion. The enterprise value is $22.57 billion.
| Market Cap | 18.73B |
| Enterprise Value | 22.57B |
Important Dates
The last earnings date was Thursday, July 31, 2025, before market open.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 146.61 million shares outstanding. The number of shares has increased by 0.31% in one year.
| Current Share Class | 146.61M |
| Shares Outstanding | 146.61M |
| Shares Change (YoY) | +0.31% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 89.56% |
| Float | 146.22M |
Valuation Ratios
The trailing PE ratio is 12.22 and the forward PE ratio is 8.29. Biogen's PEG ratio is 8.29.
| PE Ratio | 12.22 |
| Forward PE | 8.29 |
| PS Ratio | 1.87 |
| Forward PS | 2.01 |
| PB Ratio | 1.06 |
| P/TBV Ratio | 11.19 |
| P/FCF Ratio | 9.47 |
| P/OCF Ratio | 8.85 |
| PEG Ratio | 8.29 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.00, with an EV/FCF ratio of 11.40.
| EV / Earnings | 14.74 |
| EV / Sales | 2.26 |
| EV / EBITDA | 7.00 |
| EV / EBIT | 9.11 |
| EV / FCF | 11.40 |
Financial Position
The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.37.
| Current Ratio | 2.50 |
| Quick Ratio | 1.52 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 1.97 |
| Debt / FCF | 3.33 |
| Interest Coverage | 9.82 |
Financial Efficiency
Return on equity (ROE) is 9.13% and return on invested capital (ROIC) is 6.62%.
| Return on Equity (ROE) | 9.13% |
| Return on Assets (ROA) | 5.62% |
| Return on Invested Capital (ROIC) | 6.62% |
| Return on Capital Employed (ROCE) | 9.85% |
| Revenue Per Employee | $1.31M |
| Profits Per Employee | $201,249 |
| Employee Count | 7,605 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 1.02 |
Taxes
In the past 12 months, Biogen has paid $267.20 million in taxes.
| Income Tax | 267.20M |
| Effective Tax Rate | 14.86% |
Stock Price Statistics
The stock price has decreased by -36.17% in the last 52 weeks. The beta is 0.13, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -36.17% |
| 50-Day Moving Average | 130.00 |
| 200-Day Moving Average | 140.88 |
| Relative Strength Index (RSI) | 46.43 |
| Average Volume (20 Days) | 1,490,156 |
Short Selling Information
The latest short interest is 3.90 million, so 2.66% of the outstanding shares have been sold short.
| Short Interest | 3.90M |
| Short Previous Month | 4.00M |
| Short % of Shares Out | 2.66% |
| Short % of Float | 2.66% |
| Short Ratio (days to cover) | 3.08 |
Income Statement
In the last 12 months, Biogen had revenue of $10.00 billion and earned $1.53 billion in profits. Earnings per share was $10.45.
| Revenue | 10.00B |
| Gross Profit | 7.56B |
| Operating Income | 2.48B |
| Pretax Income | n/a |
| Net Income | 1.53B |
| EBITDA | 3.22B |
| EBIT | 2.48B |
| Earnings Per Share (EPS) | $10.45 |
Balance Sheet
The company has $2.76 billion in cash and $6.59 billion in debt, giving a net cash position of -$3.84 billion or -$26.16 per share.
| Cash & Cash Equivalents | 2.76B |
| Total Debt | 6.59B |
| Net Cash | -3.84B |
| Net Cash Per Share | -$26.16 |
| Equity (Book Value) | 17.63B |
| Book Value Per Share | 120.29 |
| Working Capital | 4.78B |
Cash Flow
In the last 12 months, operating cash flow was $2.12 billion and capital expenditures -$138.00 million, giving a free cash flow of $1.98 billion.
| Operating Cash Flow | 2.12B |
| Capital Expenditures | -138.00M |
| Free Cash Flow | 1.98B |
| FCF Per Share | $13.50 |
Margins
Gross margin is 75.58%, with operating and profit margins of 24.79% and 15.31%.
| Gross Margin | 75.58% |
| Operating Margin | 24.79% |
| Pretax Margin | 17.98% |
| Profit Margin | 15.31% |
| EBITDA Margin | 32.23% |
| EBIT Margin | 24.79% |
| FCF Margin | 19.79% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.31% |
| Shareholder Yield | -0.31% |
| Earnings Yield | 8.17% |
| FCF Yield | 10.56% |
Analyst Forecast
The average price target for Biogen is $187.96, which is 47.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $187.96 |
| Price Target Difference | 47.13% |
| Analyst Consensus | Buy |
| Analyst Count | 27 |
| Revenue Growth Forecast (5Y) | -0.17% |
| EPS Growth Forecast (5Y) | 9.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3.16 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.16 |
| Piotroski F-Score | 6 |